Atlas Trials

Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study

Clinical trial NCT04230304 · TERMINATED

Trial details

NCT number
NCT04230304
Sponsor
Mayo Clinic
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Chronic Lymphocytic LeukemiaRecurrent Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Small Lymphocytic Lymphoma
Start date
2020-11-11
Primary completion
2023-05-01
Enrollment
8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.